{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:09:18Z","timestamp":1792012158599,"version":"4.4.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a considerable disease burden. Existing treatment options are limited and often suboptimal; a high unmet need exists for effective targeted therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore the effects of spesolimab treatment in patients with HS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This randomized double-blind placebo-controlled proof-of-clinical-concept (PoCC) study was conducted at 25 centres across 12 countries from 3 May 2021 to 21 April 2022. Patients had moderate-to-severe HS for \u2265 1 year before enrolment. Patients were randomized (2 : 1) to receive a loading dose of 3600-mg intravenous spesolimab (1200 mg at weeks 0, 1 and 2) or matching placebo, followed by maintenance with either 1200-mg subcutaneous spesolimab every 2 weeks from weeks 4 to 10 or matching placebo. The primary endpoint was the percentage change from baseline in total abscess and inflammatory nodule (AN) count at week 12. Secondary endpoints were the absolute change from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4), percentage change from baseline in draining tunnel (dT) count, the proportion of patients achieving a dT count of 0, absolute change from baseline in the revised Hidradenitis Suppurativa Area and Severity Index (HASI-R), the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR50), the proportion of patients with \u2265 1 flare (all at week 12) and patient-reported outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In this completed trial, randomized patients (n = 52) received spesolimab (n = 35) or placebo (n = 17). The difference vs. placebo in least squares mean is reported. At week 12, the percentage change in total AN count was similar between treatment arms: \u20134.1% [95% confidence interval (CI) \u201331.7 to 23.4]. There was greater numerical improvement in the spesolimab arm, as measured by IHS4 (13.9, 95% CI \u201325.6 to \u20132.3); percentage change from baseline in dT count (\u201396.6%, 95% CI \u2013154.5 to \u201338.8); and the proportion of patients achieving a dT count of 0 (18.3%, 95% CI \u20137.9 to 37.5). Spesolimab treatment also improved HASI-R and HiSCR50 vs. placebo. Spesolimab demonstrated a favourable safety profile, similar to that observed in trials in other diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This exploratory PoCC study supports the development of spesolimab as a new therapeutic option in HS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae144","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T08:52:40Z","timestamp":1712307160000},"page":"508-518","source":"Crossref","is-referenced-by-count":43,"title":["Proof-of-concept study exploring the effect of spesolimab\u00a0in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial"],"prefix":"10.1093","volume":"191","author":[{"given":"Afsaneh","family":"Alavi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol P","family":"Prens","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus University Medical Center , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B","family":"Kimball","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Frew","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, UNSW Medicine and Health , Sydney, NSW , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G","family":"Krueger","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology, The Rockefeller University , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutirtha","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim Am Rhein , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heli","family":"Gao","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Shanghai Pharmaceuticals Co. Ltd , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim Am Rhein , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie B","family":"Ivanoff","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim Am Rhein , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00a0C","family":"Hernandez\u00a0Daly","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim Am Rhein , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-2608","authenticated-orcid":false,"given":"Christos C","family":"Zouboulis","sequence":"additional","affiliation":[{"name":"Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg , Dessau , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"2024091723524215900_ljae144-B1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"key":"2024091723524215900_ljae144-B2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"key":"2024091723524215900_ljae144-B3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723524215900_ljae144-B4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/jdv.16183","article-title":"Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study","volume":"34","author":"Martorell","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723524215900_ljae144-B5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723524215900_ljae144-B6","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa? \u201315 years after","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp Dermatol"},{"key":"2024091723524215900_ljae144-B7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/jdv.14686","article-title":"A cross-sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP)","volume":"32","author":"Delany","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723524215900_ljae144-B8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000496234","article-title":"Development of HiSQOL: a hidradenitis suppurativa-specific quality of life instrument","volume":"5","author":"Thorlacius","year":"2019","journal-title":"Skin Appendage Disord"},{"key":"2024091723524215900_ljae144-B9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaad.2006.08.061","article-title":"Quality of life impairment in hidradenitis suppurativa: a study of 61 cases","volume":"56","author":"Wolkenstein","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2024091723524215900_ljae144-B10","author":"Ingram"},{"key":"2024091723524215900_ljae144-B11","author":"Kirby"},{"key":"2024091723524215900_ljae144-B12","first-page":"18","article-title":"Hidradenitis suppurativa","volume-title":"Nat Rev Dis Primers","author":"Sabat","year":"2020"},{"key":"2024091723524215900_ljae144-B13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024091723524215900_ljae144-B14","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.16147","article-title":"Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa","volume":"34","author":"Zouboulis","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723524215900_ljae144-B15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/pharmaceutics14010044","article-title":"Hidradenitis suppurativa and comorbid disorder biomarkers, druggable genes, new drugs and drug repurposing \u2013 a molecular meta-analysis","volume":"14","author":"Zouboulis","year":"2021","journal-title":"Pharmaceutics"},{"key":"2024091723524215900_ljae144-B16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdin.2020.05.005","article-title":"Hidradenitis suppurativa is an autoinflammatory keratinization disease: a review of the clinical, histologic, and molecular evidence","volume":"1","author":"Frew","year":"2020","journal-title":"JAAD Int"},{"key":"2024091723524215900_ljae144-B17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fmed.2020.00068","article-title":"Hidradenitis suppurativa: current understanding of pathogenic mechanisms and suggestion for treatment algorithm","volume":"7","author":"Seyed Jafari","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2024091723524215900_ljae144-B18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/bjd\/ljac096","article-title":"Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies","volume":"188","author":"Schell","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024091723524215900_ljae144-B19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"key":"2024091723524215900_ljae144-B20","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2024091723524215900_ljae144-B21","doi-asserted-by":"crossref","first-page":"e139930","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"JCI Insight"},{"key":"2024091723524215900_ljae144-B22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"2024091723524215900_ljae144-B23","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024091723524215900_ljae144-B24","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211055920","article-title":"New perspectives on the treatment of hidradenitis suppurativa","volume":"12","author":"Amat-Samaranch","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"2024091723524215900_ljae144-B25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000529848","article-title":"Tunnels in hidradenitis suppurativa: active inflammatory entities with specific molecular and genetic profiles \u2013 a narrative review","volume":"239","author":"Krajewski","year":"2023","journal-title":"Dermatology"},{"key":"2024091723524215900_ljae144-B26","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/jdv.14389","article-title":"Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa","volume":"31","author":"Thomi","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2024091723524215900_ljae144-B27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.16019","article-title":"Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop","volume":"178","author":"Hessam","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024091723524215900_ljae144-B28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/AOG.0000000000004321","article-title":"Hidradenitis Suppurativa Foundation Women's Health Subcommittee. Clinical epidemiology and management of hidradenitis suppurativa","volume":"137","author":"Sayed","year":"2021","journal-title":"Obstet Gynecol"},{"key":"2024091723524215900_ljae144-B29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijwd.2020.02.006","article-title":"Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice","volume":"6","author":"Touhouche","year":"2020","journal-title":"Int J Womens Dermatol"},{"key":"2024091723524215900_ljae144-B30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization \u2013 systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723524215900_ljae144-B31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jdv.18163","article-title":"Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US","volume":"36","author":"Ingram","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 1","key":"2024091723524215900_ljae144-B32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/exd.14338","article-title":"Target molecules for future hidradenitis suppurativa treatment","volume":"30","author":"Zouboulis","year":"2021","journal-title":"Exp Dermatol"},{"key":"2024091723524215900_ljae144-B33","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"key":"2024091723524215900_ljae144-B34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s43441-021-00299-4","article-title":"Proof of concept: drug selection? Or dose selection? Thoughts on multiplicity issues","volume":"55","author":"Li","year":"2021","journal-title":"Ther Innov Regul Sci"},{"key":"2024091723524215900_ljae144-B35","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024091723524215900_ljae144-B36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jid.2017.09.008","article-title":"Increased suicide risk in patients with hidradenitis suppurativa","volume":"138","author":"Thorlacius","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2024091723524215900_ljae144-B37","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2024091723524215900_ljae144-B38","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"key":"2024091723524215900_ljae144-B39","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data","volume":"82","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024091723524215900_ljae144-B40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/ced.14448","article-title":"Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab","volume":"46","author":"Frew","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2024091723524215900_ljae144-B41","author":"AnaptysBio"},{"key":"2024091723524215900_ljae144-B42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","article-title":"Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study","volume":"11","author":"Mrowietz","year":"2021","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae144\/58379077\/ljae144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/4\/508\/59122471\/ljae144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/4\/508\/59122471\/ljae144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T23:52:57Z","timestamp":1726617177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/4\/508\/7641056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,5]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae144","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,4,5]]}}}